Selenoergothionein as a Potential Inhibitor against Amyloid ÃÂ²-Protein (AÃÂ²): Docking and Molecular Dynamics StudiesMadhu Sudhana Saddala, Pradeep Kiran Jangampalli, Adi Vengala Rao Patchava and Usha Rani A*
DBT-Bioinformatics center, Department of Zoology, Sri Venkateswara University, Tirupati, A.P, India
- *Corresponding Author:
- Usha Rani A
Department of Zoology
Sri Venkateswara University
Tirupati, A.P, India
E-mail: [email protected]
Received date April 06, 2016; Accepted date April 30, 2016; Published date May 07, 2016
Citation: Saddala MS, Kiran JAP, Patchava VR, Rani AU (2016) Selenoergothionein as a Potential Inhibitor against Amyloid Β-Protein (Aβ): Docking and Molecular Dynamics Studies. Int J Biomed Data Min 5:120. doi:10.4172/2090-4924.1000120
Copyright: © 2016 Saddala MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Alzheimer‘s disease (AD) is a progressive neurodegenerative disorder, encircling the deterioration of cognitive functions and behavioral changes, characterized by the aggregation of amyloid β-protein (Aβ) into fibrillar amyloid plaques in elected areas of the brain with the lipid-carrier protein apolipoprotein E (apoE), the microtubule associated protein tau, and the presynaptic protein α-synuclein. High levels of fibrillary Aβ, the main constituent of senile plaques, are deposited in the AD brain that outcome in the thrashing of synapses, neurons and destruction of neuronal role. Aβ is derived from the amyloid precursor protein through sequential protein cleavage by aspartyl protease, β-secretase and presenilin-dependent β-secretase triggering a spill of events such as oxidative damage, neurotoxicity, and inflammation that contributes to the progression of AD. Therefore the Aβ protein may be a target for anti-Alzheimer drugs. Aβ proteinwas retrieved from the Protein data bankand energy minimized and subjectedto molecular dynamic simulations using NAMD 2.9 software with CHARMM27 force field inwater. The Aβ protein structure was energy minimized by 25,000 steps for 500 ps and pretend 100,000 steps for 2ns.The ergothionein and selenoergothionein, which were found to exhibit amyloid inhibitory effect, were selected and the 3D structure files of those compounds were retrieved from Zinc database. The two compounds were then dockedinto the active site of Aβ protein with AutoDock Vina in PyRx Virtual Screening tool.The two compounds were showed best binding energies of -9.8, and -7.9 kcal/mol correspondingly. The binding interactions of compounds with active site of Aβ proteinmodel suggested that the amino acid residues (SER8, GLN15, and LYS16) play a key role for drug design.The predicted pharmalogical properties of two compounds, among them selenoergothionein is well within the range of a drug molecule with good ADME profile. Therefore, would be interesting towards progress of persuasive inhibitor against Aβ protein.